IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Predictive Factors for Major Bleeding Risk in Patients Admitted in a Palliative Care Unit (RHESO)
This study has been completed.
Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Collaborator:
Ministry of Health, France
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier:
NCT01056978
First received: January 26, 2010
Last updated: August 6, 2013
Last verified: August 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Even if most patients in palliative care units presented with well-recognized risks factors of venous thromboembolism (VTE) (eg: active cancer, bed rest, previous history of venous thrombosis), the incidence of VTE in palliative setting is unknown. By consequence, the efficacy and safety of antithrombotic prophylaxis in such a population is not established. Indeed, patients admitted in palliative care units were not included in trials evaluating the potential effect of antithrombotic drugs in regard to their poor prognosis at short term. In addition, the main role of prophylaxis is to prevent sudden death from pulmonary emboli and is thus a life prolonging therapy which is viewed as counterintuitive to palliative care philosophy and inappropriate on grounds of futility. Nevertheless, the current use of Low Molecular Weight Heparin in palliative care units seems to increase particularly in patients with advanced malignancy. The identification of high hemorrhagic risks in palliative care patients could help the decision of antithrombotic prophylaxis initiation. For this, the investigators conducted a multicenter prospective longitudinal study.
| Condition |
|---|
| Hemorrhage |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Predictive Factors for Major Bleeding Risk in Patients Admitted in a Palliativecare Unit - Etude RHESO - Etude Monocentrique |
Resource links provided by NLM:
Further study details as provided by Centre Hospitalier Universitaire de Saint Etienne:
Primary Outcome Measures:
- The primary outcome is the symptomatic occurrence of major and clinical relevant bleeding during the three months study period. [ Time Frame: 3 month ]
Secondary Outcome Measures:
- Predictive factors for major bleeding [ Time Frame: 3 month ]
- Incidence of venous thomboembolic symptomatic disease [ Time Frame: 3 month ]
| Enrollment: | 1230 |
| Study Start Date: | April 2010 |
| Study Completion Date: | December 2012 |
| Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
patients
Patients admitted in a palliative care unit
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
community sample
Criteria
Inclusion Criteria:
- 18 years
- admitted in a palliative care unit for a cancer, a pulmonary, a cardiac or a neurologic advanced disease
Exclusion Criteria:
- life prognosis less than 48 hours
- patients treated with curative doses of antithrombotic therapy
- patients with follow up of 3 months is not possible
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01056978
Please refer to this study by its ClinicalTrials.gov identifier: NCT01056978
Locations
| France | |
| Centre Gérontologique Saint-Thomas | |
| Aix en Provence, France, 13100 | |
| Hôpital Jean Minjoz - CHU de Besançon | |
| Besançon, France, 25000 | |
| CH de Chambéry | |
| Chambery, France, 73011 | |
| Hôpital Nord - CHU Clermont-Ferrand | |
| Cébazat, France, 63118 | |
| CH de Gap | |
| GAP, France, 05000 | |
| La Maison de Gardanne | |
| Gardanne, France, 13120 | |
| CHU Grenoble | |
| Grenoble, France, 38043 | |
| CH Saint-Philibert | |
| Lomme, France, 59462 | |
| CH Luynes - CHU Tours | |
| Luynes, France, 37230 | |
| Hôpital Saint-Eloi - CHU de Montpellier | |
| Montpellier, France, 34295 | |
| CHU Nantes | |
| Nantes, France, 44000 | |
| CHU Nice | |
| Nice, France, 06200 | |
| Maison Médicale Jeanne Garnier | |
| Paris, France, 75015 | |
| Hôpital Sainte Perrine - APHP | |
| Paris, France, 75016 | |
| GH Diaconnesses Croix Saint-Marie | |
| Paris, France, 75571 | |
| CHU Lyon Sud | |
| Pierre Bénite, France, 69495 | |
| CH Puteaux | |
| Puteaux, France, 92800 | |
| CHU de Saint-Etienne | |
| Saint-Etienne, France, 42100 | |
| Hôpital Joseph Ducuing - CH Saint-Gaudens | |
| Toulouse, France, 31076 | |
| Hôpital Paul Brousse APHP | |
| Villejuif, France, 94800 | |
Sponsors and Collaborators
Centre Hospitalier Universitaire de Saint Etienne
Ministry of Health, France
Investigators
| Study Director: | Bernard TARDY, PHD | CIC-EC (CIE3) |
More Information
| Responsible Party: | Centre Hospitalier Universitaire de Saint Etienne |
| ClinicalTrials.gov Identifier: | NCT01056978 History of Changes |
| Other Study ID Numbers: |
0908039 2009-A01234-53 ( Other Identifier: AFSSAPS ) |
| Study First Received: | January 26, 2010 |
| Last Updated: | August 6, 2013 |
Keywords provided by Centre Hospitalier Universitaire de Saint Etienne:
|
palliative care unit bleeding thromboembolic hemorrhagic risk antithrombotic prophylaxis |
Additional relevant MeSH terms:
|
Hemorrhage Pathologic Processes |
ClinicalTrials.gov processed this record on August 18, 2017